Sanofi (SNY) Set to Release Quarterly Earnings on Friday

Key Points

• Sanofi is expected to report Q3 2026 earnings before the market opens on October 30. Analysts project earnings of $1.63 per share on revenue of $14.91 billion, with a conference call scheduled for 8:30 a.m. ET.
• In its previous quarter, Sanofi earned $2.41 per share on $13.36 billion in revenue, with sales up 16% year over year. Analysts forecast full-year EPS of $5.00 and next-year EPS of $5.19.
• Sanofi shares recently traded at $41.96, below the $49.50 analyst consensus target. Wall Street’s overall rating is Hold, with seven Buy, twelve Hold, one Sell and one Strong Buy recommendation.

Sanofi (NASDAQ:SNY - Get Free Report) is anticipated to issue its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect Sanofi to post earnings of $1.63 per share and revenue of $14.91 billion for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, October 30, 2026 at 8:30 AM ET.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported $2.41 earnings per share for the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The firm had revenue of $13.36 billion during the quarter. During the same period in the previous year, the company posted $3.24 earnings per share. Sanofi's revenue for the quarter was up 16.0% on a year-over-year basis. On average, analysts expect Sanofi to post $5.00 EPS for the current fiscal year and $5.19 EPS for the next fiscal year.

Sanofi Stock Performance

SNY opened at $41.96 on Friday. The business's 50-day moving average price is $42.47 and its two-hundred day moving average price is $43.57. Sanofi has a 1 year low of $39.07 and a 1 year high of $52.68. The company has a market capitalization of $101.73 billion, a price-to-earnings ratio of 21.97, a P/E/G ratio of 1.26 and a beta of 0.33. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.99 and a quick ratio of 0.64.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SNY. HSBC reaffirmed a "buy" rating on shares of Sanofi in a research report on Thursday, September 10th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of Sanofi in a research report on Tuesday, September 29th. Royal Bank Of Canada initiated coverage on Sanofi in a research report on Tuesday, September 8th. They issued a "sector perform" rating on the stock. UBS Group restated a "neutral" rating on shares of Sanofi in a research note on Thursday, September 17th. Finally, Wall Street Zen downgraded Sanofi from a "buy" rating to a "hold" rating in a research report on Saturday, October 3rd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $49.50.

Sanofi Company Profile

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company's portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.